InsiderTrades.com logo
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
From Brownstone Research   |   Ad
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.
So please click here to see the details because a lot of people could get rich.

CYTH Insider Trading

Insider Ownership Percentage: 29.78%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Cyclo Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Share Price & Price History

Current Price: $0.63
Price Change: ▲ Price Increase of +0.01 (1.61%)
As of 12/20/2024 06:31 PM ET

This chart shows the closing price history over time for CYTH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
From Weiss Ratings   |   Ad
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Find out details on these three critical Nvidia partners immediately.

Cyclo Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2023Rafael Holdings, Inc.Major ShareholderBuy4,000,000$1.25$5,000,000.006,514,970View SEC Filing Icon  
4/20/2023Jeffrey TateCOOBuy29,941$0.71$21,258.1162,101View SEC Filing Icon  
4/20/2023Markus SiegerDirectorBuy59,881$0.71$42,515.51161,051View SEC Filing Icon  
4/20/2023N. Scott FineCEOBuy299,402$0.71$212,575.42444,402View SEC Filing Icon  
9/21/2022Francis Patrick OstronicDirectorBuy5,000$1.76$8,800.00150,687View SEC Filing Icon  
9/21/2022Francis Patrick OstronicDirectorBuy5,000$1.76$8,800.00150,687View SEC Filing Icon  
5/20/2022Francis Patrick OstronicDirectorBuy5,000$2.04$10,200.00138,525View SEC Filing Icon  
5/16/2022Jeffrey TateCOOBuy3,000$2.12$6,360.0032,160View SEC Filing Icon  
4/28/2022Jeffrey TateCOOBuy635$2.50$1,587.5027,795View SEC Filing Icon  
3/29/2022Markus SiegerDirectorBuy10,000$2.73$27,300.00View SEC Filing Icon  
2/7/2022N. Scott FineCEOBuy10,334$3.58$36,995.72View SEC Filing Icon  
1/24/2022Francis Patrick OstronicDirectorBuy2,000$3.75$7,500.00View SEC Filing Icon  
1/19/2022Francis Patrick OstronicDirectorBuy1,132$4.00$4,528.00View SEC Filing Icon  
1/19/2022N. Scott FineCEOBuy5,000$3.89$19,450.00View SEC Filing Icon  
1/14/2022Francis Patrick OstronicDirectorBuy2,137$4.00$8,548.00View SEC Filing Icon  
See Full Table
First JFK… next Elon?
From Porter & Company   |   Ad
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
I share with you in this special investigative documentary.

SEC Filings (Institutional Ownership Changes) for Cyclo Therapeutics (NASDAQ:CYTH)

68.55% of Cyclo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CYTH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Cyclo Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/10/2024EPIQ Capital Group LLC817,270$1.04M0.4%-4.3%2.856%Search for SEC Filing on Google Icon
2/15/2024Founders Fund V Management LLC480,708$0.76M80.8%N/A2.115%Search for SEC Filing on Google Icon
2/15/2024Founders Fund VI Management LLC110,023$0.18M1.4%N/A0.484%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.13,134$88K0.0%+21.1%0.204%Search for SEC Filing on Google Icon
8/16/2021State Street Corp44,700$0.46M0.0%N/A0.703%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC42,577$0.44M0.0%+133.2%0.670%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.151,540$1.55M0.0%+350.4%2.383%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC18,257$0.15M0.0%N/A0.287%Search for SEC Filing on Google Icon
3/26/2021Susquehanna International Group LLP15,656$68K0.0%N/A0.249%Search for SEC Filing on Google Icon
2/17/2021Jane Street Group LLC27,892$0.12M0.0%N/A1.641%Search for SEC Filing on Google Icon
2/17/2021Worth Venture Partners LLC88,690$0.39M0.3%N/A5.217%Search for SEC Filing on Google Icon
2/16/2021Armistice Capital LLC100,000$0.44M0.0%N/A5.882%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
Read More on Cyclo Therapeutics

Today's Range

Now: $0.63
Low: $0.60
High: $0.63

50 Day Range

MA: $0.70
Low: $0.57
High: $0.81

52 Week Range

Now: $0.63
Low: $0.57
High: $2.12

Volume

26,548 shs

Average Volume

66,084 shs

Market Capitalization

$18.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Cyclo Therapeutics?

Cyclo Therapeutics' top insider investors include:
  1. Rafael Holdings, Inc (Major Shareholder)
  2. N Scott Fine (CEO)
  3. Markus Sieger (Director)
  4. Jeffrey Tate (COO)
Learn More about top insider investors at Cyclo Therapeutics.
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
From Brownstone Research   |   Ad
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.
So please click here to see the details because a lot of people could get rich.